Clinical trials: Mask
Vernal Keratoconjunctivitis
Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
The objective of this study is to compare the efficacy of two different dosing regimen of NOVA22007 (1mg/ml ciclosporin/cyclosporine) eye drops, emulsion versus placebo (vehicle of the formulation) administered four times a day…
- Trial name
- NCT01751126
- Testing
- NOVA22007 ''Ciclosporin''
- Where
- 46 sites in United States, Croatia and 9 more
- Volunteers
- 169 people
- Sponsor
- Santen SAS
Difficult Airway, Anesthesia; Functional
Air-Q Intubating Laryngeal Airway Versus the Laryngeal Mask Airway (LMA)-Proseal
Introduction: The air-QⓇ Intubating Laryngeal Airway (ILA) is a newer supraglottic airway. It is approved for use as a primary airway and as an aid for intubation in situations of anticipated or unanticipated difficult airways.
- Trial name
- NCT01328405
- Testing
- Laryngeal Mask Airway (LMA)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Wisconsin, Madison
Age-Related Macular Degeneration
Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy
This study will compare the safety and efficacy of Medidur FA treatment in one eye to the sham-treated fellow eye of subjects with geographic atrophy secondary to AMD.
- Trial name
- NCT00695318
- Testing
- Fluocinolone Acetonide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Alimera Sciences
Glaucoma
Travatan Versus Timoptic in Treating Open-angle Glaucoma or Ocular Hypertension
To evaluate the Intraocular Pressure (IOP) lowering efficacy and safety of Travoprost 0.004% compared to Timolol 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OH).
- Trial name
- NCT00763061
- Testing
- Travoprost 0.004% Ophthalmic Solution (Travatan), Timolol 0.5% Ophthalmic Solution (Timoptic)
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Alcon Research
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 1
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.
- Trial name
- NCT01853072
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac vehicle, Prednisolone acetate
- Volunteers
- 881 people
- Sponsor
- Alcon Research
Thyroid Eye Disease
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in…
- Trial name
- SatraGO-2 (NCT06106828)
- Testing
- Satralizumab
- Where
- 41 sites in United States, Canada and 8 more
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche
Acute Respiratory Insufficiency
Evaluation Of The Total Face Mask For Emergency Application In Acute Respiratory Failure
The purpose of this study is to compare the Total Face Mask™ (Respironics, Inc., Pittsburgh, PA) (covering whole face) and the standard oronasal facemask (covering nose and mouth) for the emergency treatment of patients with…
- Trial name
- NCT00686257
- Testing
- Total face mask (interface for NPPV), Comfort full or RT040 oronasal mask (interface for NPPV)
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Tufts Medical Center
Age-related Macular Degeneration
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
A randomized, double-masked, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of elamipretide in subjects with Age-Related Macular Degeneration with non-central Geographic Atrophy.
- Trial name
- ReCLAIM-2 (NCT03891875)
- Testing
- Subcutaneous elamipretide through the elamipretide delivery system
- Where
- 37 sites in United States
- Volunteers
- 176 people
- Sponsor
- Stealth BioTherapeutics Inc.
Presbyopia, Near Vision
Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia
Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia
- Conditions
- Presbyopia, Near Vision, Refractive Error, Eye Diseases
- Trial name
- CLARITY 2 (NCT05728944)
- Testing
- Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle
- Where
- 17 sites in United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- LENZ Therapeutics, Inc
Dry Eye
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
The primary objective of this study was to assess the efficacy and safety of rhNGF when administered as eye drops to patients with dry eye The secondary objectives of this study were: To assess change from baseline in Symptom…
- Trial name
- NCT03019627
- Testing
- NGF, Vehicle
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dompé Farmaceutici S.p.A
Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
This study compared the effect of ranibizumab administered as monotherapy versus ranibizumab administered in combination with verteporfin photodynamic therapy (PDT) on visual acuity in patients with symptomatic macular polypoidal…
- Trial name
- EVEREST II (NCT01846273)
- Testing
- Ranibizumab, Verteporfin PDT
- Where
- 41 sites in Hong Kong, Japan and 5 more
- Volunteers
- 321 people
- Sponsor
- Novartis Pharmaceuticals
Dry Eye Disease (DED)
Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (011516X) with Systane® Ultra Multidose for 90 days in participants with Dry Eye Disease (DED).
- Trial name
- NCT04393441
- Testing
- 011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
- Where
- 26 sites in United States
- Volunteers
- 400 people
- Sponsor
- Allergan
Anaesthesia
Effect of Laryngeal Mask Cuff Pressure in Geriatric Patients
Laryngeal Mask is widely used for air-way management during anaesthesia. Pharyngolaryngeal morbidity linked to laryngeal mask use is related to correct choice of mask size, placement technique, placement of the laryngeal mask in…
- Trial name
- NCT02189954
- Testing
- The placement according to the manufacturer's instructions, Cuff inner pressure was held below 44 mmHg
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Dokuz Eylul University
Primary Open-angle Glaucoma and Ocular Hypertension
Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6
This is a randomized, double-masked, parallel-group, multi-center study. Subjects diagnosed with POAG or OHT who meet eligibility criteria at Visit 1 (Screening) will wash out their current topical IOP lowering medication(s), if…
- Trial name
- NCT03858894
- Testing
- DE-117 Ophthalmic Solution QD, DE-117 Ophthalmic Solution BID
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Santen Inc.
Dry Eye Disease
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with…
- Trial name
- NCT04567329
- Testing
- NOV03, Saline Solution
- Where
- 35 sites in United States
- Volunteers
- 620 people
- Sponsor
- Bausch & Lomb Incorporated
Diabetic Macular Edema
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered…
- Trial name
- NCT05151731
- Testing
- Vamikibart, Ranibizumab
- Where
- 74 sites in United States, Argentina and 7 more
- Volunteers
- 394 people
- Sponsor
- Hoffmann-La Roche
Presbyopia
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Safety and efficacy of POS in participants with presbyopia
- Trial name
- VEGA-3 (NCT06542497)
- Testing
- 0.75% phentolamine ophthalmic solution
- Where
- 39 sites in United States
- Volunteers
- 569 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Open-angle Glaucoma, Ocular Hypertension
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
To evaluate ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution.
- Trial name
- NCT02558374
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol Maleate Ophthalmic Solution 0.5% BID
- Where
- United States
- Volunteers
- 708 people
- Sponsor
- Aerie Pharmaceuticals
Diabetic Macular Edema
Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement
This study evaluated the safety and efficacy of ranibizumab on retinal edema and visual acuity in patients with diabetic macular edema with center involvement.
- Trial name
- RESOLVE (NCT00284050)
- Testing
- Ranibizumab 0.3 mg, Ranibizumab 0.5 mg
- Where
- Switzerland
- Volunteers
- 151 people
- Sponsor
- Novartis
Diabetic Macular Edema
A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to…
- Trial name
- RESTORE (NCT00687804)
- Testing
- Ranibizumab, Laser
- Where
- 13 sites in Australia, Belgium and 11 more
- Volunteers
- 345 people
- Sponsor
- Novartis